Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia

Enkhtsetseg Purev, Xin Tian, Georg Aue, Jeremy Pantin, Phuong Vo, Reem Shalabi, Robert N. Reger, Lisa Cook, Catalina Ramos, Elena Cho, Tat'yana Worthy, Hanh Khuu, David Stroncek, Neal S. Young, Richard W. Childs

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Allogeneic haematopoietic stem cell transplantation is curative for severe aplastic anaemia (SAA) unresponsive to immunosuppressive therapy. To reduce chronic graft-versus-host disease (GVHD), which occurs more frequently after peripheral blood stem cell (PBSC) transplantation compared to bone-marrow transplantation (BMT), and to prevent graft rejection, we developed a novel partial T-cell depleted transplant that infuses high numbers of granulocyte colony-stimulating factor-mobilized CD34+ selected PBSCs combined with a BMT-equivalent dose of non-mobilized donor T-cells. Fifteen patients with refractory SAA received cyclophosphamide, anti-thymocyte globulin and fludarabine conditioning, and were transplanted with a median 8 × 106 CD34+ cells/kg and 2 × 107 non-mobilized CD3+ T-cells/kg from human leucocyte antigen-matched sibling donors. All achieved sustained engraftment with only two developing acute and two developing chronic GVHD. With a 3·5-year median follow-up, 86% of patients survived and were transfusion-independent. When compared to a retrospective cohort of 56 bone-marrow failure patients that received the identical transplant preparative regimen and GVHD prophylaxis with the exception that the allograft contained unmanipulated PBSCs, partial T-cell depleted transplant recipients had delayed donor T-cell chimerism and relative reduction of 75% in the incidence of acute grade II-IV GVHD (13% vs. 52%; P = 0·010) and of 82% in chronic GVHD (13% vs. 72%; P = 0·0004). In multivariate analysis, partial T-cell depleted transplants remained significantly associated with a reduced risk of GVHD. In conclusion, for patients with refractory SAA, this novel transplant strategy achieves excellent engraftment and survival when compared to unmanipulated PBSC transplants and dramatically reduces the incidence of both acute and chronic GVHD.

Original languageEnglish (US)
Pages (from-to)950-960
Number of pages11
JournalBritish Journal of Haematology
Volume176
Issue number6
DOIs
StatePublished - Mar 1 2017

Keywords

  • CD34 selected PBSC
  • allogeneic stem cell transplantation
  • bone marrow transplantation
  • partial T-cell depleted transplant
  • severe aplastic anaemia

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Allogeneic transplantation using CD34<sup>+</sup> selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia'. Together they form a unique fingerprint.

  • Cite this

    Purev, E., Tian, X., Aue, G., Pantin, J., Vo, P., Shalabi, R., Reger, R. N., Cook, L., Ramos, C., Cho, E., Worthy, T., Khuu, H., Stroncek, D., Young, N. S., & Childs, R. W. (2017). Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia. British Journal of Haematology, 176(6), 950-960. https://doi.org/10.1111/bjh.14448